Natco Pharma Faces ₹49.23 Crore NPPA Demand for Alleged Drug Overcharging

Natco Pharma has received a demand notice from India's National Pharmaceutical Pricing Authority (NPPA) for approximately ₹49.23 crore, citing allegations of overcharging for two drugs. The company informed regulators that this demand is unlikely to significantly affect its financial or operational performance.

The Demand Notice

The demand notice, dated May 12, 2026, and received by Natco Pharma on the same date, relates to alleged overcharging for two of its pharmaceutical products between April and November 2023. Natco Pharma also cited technical and procedural issues for the delay in disclosing this notice.

Regulatory Environment in India

This development highlights the strict regulatory scrutiny pharmaceutical companies face in India regarding drug pricing. The NPPA is empowered to cap prices of essential medicines and take action against manufacturers found to be violating these regulations. Such actions can involve penalties, and potentially recovery of overcharged amounts.

Company's Position

Natco Pharma's statement that the notice will have "no material impact" indicates the company believes its pricing practices were compliant or that any potential financial implications are manageable within its existing operations. Companies in this sector often have robust mechanisms to address regulatory queries and potential disputes.

Industry Peers and Pricing

Major Indian pharmaceutical firms, including Sun Pharma, Dr. Reddy's Laboratories, and Cipla, operate within the NPPA's price control framework. These companies have historical experience navigating similar pricing pressures and regulatory actions, often relying on compliance strategies and legal recourse.

Financial Context

As of March 31, 2024, Natco Pharma reported contingent liabilities of ₹650.5 crore on a standalone basis, which could potentially cover provisions for regulatory matters. For the fiscal year ended March 31, 2024, the company reported consolidated revenue of ₹3,821 crore and a net profit of ₹921 crore.

What to Watch Next

Investors will be monitoring Natco Pharma's formal response to the NPPA and any further clarifications regarding the disclosure delay. The NPPA's subsequent actions and any precedents set by similar ongoing cases will also be key factors.